Compare AbbVie Inc (ABBV) vs Ecolab Inc. (ECL) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

ECL trades at $283.08, down 0.1% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $1.70, meeting expectations, and maintains strong profitability with a net income margin of 12.8%. Recent acquisition of CoolIT for $4.75B enhances its AI cooling portfolio, positioning for long-term growth. Cash flow from operations remains robust at $3.0B in 2025, though net cash flow turned negative due to significant investing activities.

Outlook is positive with 73% analyst buy ratings and a consensus price target of $326.17, implying 15% upside. Risks include rising costs and integration challenges from acquisitions. The stock's high P/E of 38.39 suggests premium valuation, requiring sustained earnings growth to justify current levels.